Cara Therapeutics, Inc. (CARA) financial statements (2020 and earlier)

Company profile

Business Address 4 STAMFORD PLAZA
STAMFORD, CT 06902
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:218249136156183206132
Cash and cash equivalents18351814159718
Short-term investments13715897120146109114
Other undisclosed cash, cash equivalents, and short-term investments6356202221  
Restricted cash and investments  00000
Receivables2222210
Prepaid expense9988546
Other undisclosed current assets(63)(56)(20)(22)(21) 0
Total current assets:166203125144168211139
Noncurrent Assets
Operating lease, right-of-use asset33  
Property, plant and equipment1111111
Long-term investments and receivables6356202221  
Long-term investments6356202221  
Restricted cash and investments0000000
Other undisclosed noncurrent assets  33   
Total noncurrent assets:676025262311
TOTAL ASSETS:233264150171191213140
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:20211313141413
Accounts payable91025434
Accrued liabilities1111100
Employee-related liabilities3321221
Other undisclosed accounts payable and accrued liabilities7886697
Deferred revenue2227  
Debt11     
Contract with customer, liability2628272922
Other undisclosed current liabilities  11   
Total current liabilities:43484042404335
Noncurrent Liabilities
Long-term debt and lease obligation34     
Operating lease, liability34  
Liabilities, other than long-term debt  610172032
Contract with customer, liability610151830
Deferred rent credit    222
Total noncurrent liabilities:34610172032
Total liabilities:46524652576367
Stockholders' equity
Stockholders' equity attributable to parent18721210011513415073
Common stock0000000
Additional paid in capital587584439431428423327
Accumulated other comprehensive income (loss)0000(0)0(0)
Accumulated deficit(401)(372)(339)(316)(294)(274)(254)
Total stockholders' equity:18721210011513415073
Other undisclosed liabilities and equity  44   
TOTAL LIABILITIES AND EQUITY:233264150171191213140

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Gross profit:5654653
Operating expenses(34)(40)(29)(28)(28)(26)(21)
Operating loss:(30)(34)(24)(23)(22)(20)(18)
Nonoperating income
(Other Nonoperating income)
1111110
Loss from continuing operations before income taxes:(29)(33)(23)(22)(21)(19)(17)
Income tax benefit0000000
Net loss available to common stockholders, diluted:(29)(33)(23)(22)(21)(19)(17)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(29)(33)(23)(22)(21)(19)(17)
Other comprehensive income (loss)0(0)00(0)  
Comprehensive loss:(29)(33)(23)(22)(21)(19)(17)
Other undisclosed comprehensive income, net of tax, attributable to parent     00
Comprehensive loss, net of tax, attributable to parent:(29)(33)(23)(22)(21)(19)(17)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: